Sugi Predict

Sugi Predict / Compounds / SCHEMBL282318

SCHEMBL282318

SCHEMBL282318

CCCCc1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 6/20 0.67
▸ SMN1; SMN2 Q16637 3/20 0.67
▸ LMNA P02545 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ TSHR P16473 1/20 0.54
▸ FFAR1 O14842 1/20 0.51
▸ FFAR4 Q5NUL3 1/20 0.51
▸ CA1 P00915 3/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA12 O43570 1/20 0.50
▸ AKT1 P31749 1/20 0.50
▸ HPGD P15428 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CNR2 P34972 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981061 0.94 CA2 (0.68) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL282436 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL282368 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL282149 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL3684557 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL10610516 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL282526 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL10609781 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL283020 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1
SCHEMBL283112 0.92 CA2 (0.66) CA2SMN1; SMN2LMNAHTTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119490439-A Preparation method of arylsulfonyl amino quaternary ammonium salt antibacterial agent 苏州华道生物药业股份有限公司 2025-02-21 — — CN claimed
CN-119425423-A Positively charged composite membrane and preparation method and application thereof 中国石油化工股份有限公司 2025-02-14 — — CN claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 — — EP claimed
US-20250312362-A1 INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2025-10-09 — — US disclosed
EP-4525851-A1 INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Merck Sharp & Dohme LLC (US) 2025-03-26 — — EP disclosed
CN-119490439-A Preparation method of arylsulfonyl amino quaternary ammonium salt antibacterial agent 苏州华道生物药业股份有限公司 2025-02-21 — — CN disclosed
CN-119425423-A Positively charged composite membrane and preparation method and application thereof 中国石油化工股份有限公司 2025-02-14 — — CN disclosed
WO-2024235876-A1 PYRIDOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS FERNANDEZ CAPETILLO OSCAR (SE) 2024-11-21 — — WO disclosed
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 — — US disclosed
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME RAPPTA THERAPEUTICS OY (FI) 2024-05-30 — — US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 — — EP disclosed
EP-1140984-A1 SELECTIVE INHIBITORS OF MMP-12 Aventis Pharmaceuticals Inc. (US) 2001-10-10 — — EP disclosed
US-6262080-B1 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase AVANTIS PHARMACEUTICALS INC. 2001-07-17 — — US disclosed
EP-1056743-A1 BENZAMINE DERIVATIVES MERCK PATENT GmbH (DE) 2000-12-06 — — EP disclosed
WO-2000040600-A1 SELECTIVE INHIBITORS OF MMP-12 AVENTIS PHARMACEUTICALS INC. (US) 2000-07-13 — — WO disclosed
WO-2000040577-A1 1-CARBOXYMETHYL-2-OXO-AZEPAN DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF MMP-12 AVENTIS PHARMACEUTICALS INC. (US) 2000-07-13 — — WO disclosed
WO-2000040553-A1 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES AVENTIS PHARMACEUTICALS INC. (US) 2000-07-13 — — WO disclosed
EP-0928291-A1 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE HOECHST MARION ROUSSEL, INC. (US) 1999-07-14 — — EP disclosed
WO-1999031092-A1 BENZAMINE DERIVATIVES MERCK PATENT GMBH (DE) 1999-06-24 — — WO disclosed
WO-1998012211-A1 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE HOECHST MARION ROUSSEL, INC. (US) 1998-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312362-A1 INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MSRB3, ABCC1, MRPS34 CA2 2766/4885SMN1; SMN2 4612/4885LMNA 3990/4885
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME PPM1A, PPP2CA, PPP3CA CA2 2400/4885SMN1; SMN2 2249/4885LMNA 4461/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB CA2 3483/4885SMN1; SMN2 2491/4885LMNA 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.